Policy

Biosimilar Legal Roundup: November 2020

November 30, 2020

Skylar Jeremias

Article

In November, the Supreme Court heard arguments on the Affordable Care Act, Europe fired up its efforts to create a more biosimilar-friendly environment, and Genentech fought to protect its bevacizumab franchise.

EC Eyes Enhancements for a Post–COVID-19 Marketplace

November 27, 2020

Tony Hagen

Article

The European Commission (EC) said it will take the lessons learned from the coronavirus disease 2019 (COVID-19) pandemic and build a better marketplace for generics and biosimilars.

Opinion: Embrace the Era of Next-Generation Biologics

November 21, 2020

Bincy P. Abraham, MD

Article

Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.

Fed Expert Describes Improving Regulatory, Policy Structure for Biosimilars

November 19, 2020

Tony Hagen

Article

Prior to the turmoil of the pandemic, the FDA and CMS were at work on shoring up the biosimilars market, and this work continues on various fronts, a regulatory/policy expert explains.

Burich: Saving Grace for Biosimilars in 2021 Will Be Bipartisan Support

November 17, 2020

Tony Hagen

Article

Despite a rocky power transition at the federal level, the compass heading for biosimilars is unchanged, said policy expert Molly Burich.

Prioritize Biosimilar Uptake in Europe, Conference Speaker Says

November 14, 2020

Skylar Jeremias

Article

In Europe, the pandemic has revealed problems within health care systems and the need to increase access to biosimilars and reform health care policies.

Medicines for Europe Takes Aim at Barriers to Entry for Biosimilars and Generics

November 5, 2020

Tony Hagen

Article

Medicines for Europe, a generic and biosimilar trade association, contends in a white paper that legal and regulatory loopholes increasingly keep competing drugs off the market.

Study: Specialty Drug Spending Net of Rebates Soars for Private Insurance, Medicare Part D

November 2, 2020

Deana Ferreri, PhD

Article

This study of specialty drug spending looks beyond rebates to evaluate growth in spending from 2010 to 2017.

ACR: UHC's New Co-pay Policy Is "Disastrous" for Patients

October 29, 2020

Tony Hagen

Article

The American College of Rheumatology (ACR) has joined with other provider groups in opposing a UnitedHealthcare (UHC) plan that could increase patient out-of-pocket costs.

Advocacy Group Details Solutions for Sluggish Biosimilar Uptake

October 28, 2020

Skylar Jeremias

Article

Arnold Ventures suggests ways the FDA and other governmental entities can get more biosimilars into circulation, faster.

x